natgillin/translations-raw huggingface dataset:
Levodopa has been associated with somnolence and episodes of sudden sleep onset. 
Levodopa je povezivana sa somnolencijom i epizodama iznenadnog nastupa sna.
Pharmaco-therapeutic group: Anti-Parkinson drugs, other dopaminergic agents, ATC code: NO4BX01 
Farmakoterapijska skupina: antiparkinsonici, ostali dopaminergici, ATK oznaka: NO4BX01
Your doctor should always begin your treatment with the standard dose of 3 times daily 1 tablet (100 mg (1 tablet)). 
Vaš liječnik će uvijek početi liječenje standardnom dozom od 1 tablete (100 mg (1 tableta)) 3 puta dnevno.
Swallow Tasmar with 1 glass of water. 
Progutajte Tasmar s 1 čašom vode.
Tasmar tablets are film-coated and should be swallowed whole because tolcapone has a bitter taste. 
Tasmar tablete su obložene filmom i moraju se progutati cijele jer tolkapon ima gorak okus.
Hepatocellular injury 
Hepatocelularno oštećenje
The onset of effect occurs after the first administration. 
Nastup učinaka javlja se nakon prve primjene.
Patients receiving multiple medications with effects on different central nervous system (CNS) pathways (e.g. antidepressants, neuroleptics, anticholinergics) may be at greater risk of developing NMS. 
Bolesnici koji primaju više lijekova s učincima na različite puteve središnjeg živčanog sustava (SŽS) (npr. antidepresivi, neuroleptici, antikolinergici) mogu imati veći rizik od razvoja NMS-a.
In addition, your doctor will stop Tasmar treatment if after 3 weeks you do not improve enough to justify the risks of continuing treatment. 
Nadalje, Vaš će liječnik prekinuti liječenje Tasmarom ako se Vaše stanje nakon 3 tjedna ne poboljša dovoljno značajno da opravda rizike od nastavka liječenja.
Tasmar 100 mg (only applicable for the outer packaging 
Tasmar 100 mg (primjenjivo samo na vanjsko pakiranje)
In clinical trials, more than 70 % of patients required a decrease in their daily levodopa dose if their daily dose of levodopa was >600 mg or if patients had moderate or severe dyskinesias before beginning treatment. 
U kliničkim ispitivanjima je kod više od 70 % bolesnika bilo potrebno smanjiti njihovu dnevnu dozu levodope, ako im je dnevna doza levodope bila >600 mg ili ako su bolesnici imali umjerene do teške diskinezije prije početka liječenja.
High levels of plasma 3-OMD have been associated with poor response to levodopa in Parkinson's disease patients. 
Visoke razine 3-OMD-a u plazmi povezivane su sa slabim odgovorom na levodopu u bolesnika s Parkinsonovom bolešću.
Do not break or crush the tablets. 
Nemojte lomiti ili mrviti tablete.
If Tasmar is to be prescribed, the patient should be informed about the signs and symptoms which may indicate liver injury, and to contact the physician immediately. 
Ako će se Tasmar propisati, bolesnik treba biti informiran o znakovima i simptomima koji mogu upućivati na oštećenje jetre i odmah se obrati liječniku.
For the remainder, when treatment was discontinued, transaminase levels returned to pre-treatment levels. 
Za preostale, kad je liječenje prekinuto, razine transaminaza vratile su se na vrijednosti prije početka liječenja.
Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with levodopa. 
Bolesnici moraju biti informirani o tome te im se mora savjetovati da budu oprezni prilikom upravljanja vozilima ili rada na strojevima tijekom liječenja levodopom.
Adverse Events 
Štetni događaji
However, if taking the next dose should be directly ahead, do not make up for the forgotten dose. 
Međutim, ako bi uzimanje sljedeće doze trebalo slijediti odmah nakon toga, nemojte nadoknađivati propuštenu dozu.
Under such a diagnosis Tasmar should be immediately discontinued and the patient should be followed up closely. 
U slučaju takve dijagnoze, Tasmar treba trenutno ukinuti i bolesnika treba pomno nadzirati.
Mutagenesis: Tolcapone was shown not to be genotoxic in a complete series of mutagenicity studies. 
Mutageneza: nije se pokazalo da je tolkapon genotoksičan u potpunoj seriji ispitivanja mutagenosti.
Symptoms have usually onset during Tasmar treatment or shortly after Tasmar has been discontinued. 
Simptomi obično počnu tijekom liječenja Tasmarom ili kratko nakon ukidanja Tasmara.
Inform your doctor about all prescription and non-prescription medications as the risk of NMS may be increased if you are taking some specific medications. 
Obavijestite svog liječnika o svim lijekovima koje uzimate, koje ste dobili na recept ili bez recepta, jer se rizik od NMS-a može povećati ako uzimate neke specifčne lijekove.
Evropská 2590/33C Prague 6 160 00 
Česká republika Evropská 2590/33C Prague 6 160 00
To reduce the risk of NMS you should not use Tasmar if your doctor says you have severe involuntary movement (dyskinesia) or a previous illness that may have been NMS. 
Radi smanjenja rizika od NMS-a, ne biste smjeli primjenjivati Tasmar ako Vaš liječnik kaže da imate teške nevoljne pokrete (diskineziju) ili prethodnu bolest koja je možda bila NMS.
Only in exceptional circumstances, when the anticipated incremental clinical benefit justifies the increased risk of hepatic reactions, should the dose be increased to 200 mg three times daily (see sections 4.4 and 4.8). 
Samo u iznimnim okolnostima, kada očekivana inkrementalna klinička korist opravdava povećani rizik od jetrenih reakcija, doza smije biti povećana na 200 mg tri puta dnevno (vidjeti dijelove 4.4 i 4.8).
Before starting treatment: If liver function tests are abnormal or there are signs of impaired liver function, Tasmar should not be prescribed. 
Prije početka liječenja: ako su testovi jetrene funkcije abnormalni ili postoje znakovi oštećene funkcije jetre, Tasmar se ne bi smio propisivati.
The first dose of the day of Tasmar should be taken together the first dose of the day of a levodopa preparation, and the subsequent doses should be given approximately 6 and 12 hours later. 
Prva dnevna doza Tasmara treba se uzeti zajedno s prvom dnevnom dozom pripravka levodope, a sljedeće doze treba dati približno 6 i 12 sati kasnije.
Therefore, if symptoms occur after discontinuing Tasmar, physicians should consider increasing the patient's levodopa dose (see section 4.2). 
Stoga, ako se simptomi jave nakon prestanka uzimanja Tasmara, liječnici bi trebali razmotriti povećanje bolesnikove doze levodope (vidjeti dio 4.2).
A double-blind trial compared Tasmar with entacapone in Parkinson's disease patients who had at least three hours of OFF time per day while receiving optimised levodopa therapy. 
Dvostruko slijepo ispitivanje usporedilo je Tasmar s entakaponom u bolesnika s Parkinsonovom bolešću koji su imali najmanje tri sata dnevno u OFF vremenu dok su primali optimiziranu terapiju levodopom.
In rats and rabbits, embryo-foetal toxicity was observed after tolcapone administration (see section 5.3). 
U štakora i kunića opažena je embriofetalna toksičnost nakon primjene tolkapona (vidjeti dio 5.3).
Tasmar is used when all other alternative medicines cannot stabilise your Parkinson's disease. 
Tasmar se primjenjuje kada svi drugi lijekovi ne mogu stabilizirati Parkinsonovu bolest.
In addition, the compound is methylated by COMT to 3-O-methyl-tolcapone and metabolised by cytochromes P450 3A4 and P450 2A6 to a primary alcohol (hydroxylation of the methyl group), which is subsequently oxidised to the carboxylic acid. 
Nadalje, spoj se metilira COMT-om u 3-O-metil-tolkapon i metabolizira se citokromima P450 3A4 i P450 2A6 u primarni alkohol (hidroksilacija metilne skupine), koji posljedično oksidira u karboksilnu kiselinu.
There were no similar renal findings in the mouse or dogs carcinogenicity studies. 
Nije bilo sličnih bubrežnih otkrića u ispitivanjima kancerogenosti na miševima ili psima.
The highest dose of tolcapone administered to humans was 800 mg three times daily, with and without levodopa coadministration, in a one week study in healthy elderly volunteers. 
Najviša doza tolkapona primijenjena u ljudi bila je 800 mg tri puta dnevno sa ili bez istodobno primijenjene levodope u jednotjednom ispitivanju na zdravim, starijim dobrovoljcima.
Toxicity to reproduction: Tolcapone, when administered alone, was shown to be neither teratogenic nor to have any relevant effects on fertility. 
Reproduktivna toksičnost: pokazalo se da tolkapon, kada se primjenjuje sam, nije teratogen niti ima bilo kakve značajne učinke na plodnost.
Absorption: Tolcapone is rapidly absorbed with a tmax of approximately 2 hours. 
Apsorpcija: tolkapon se brzo apsorbira sa tmax od približno 2 sata.
These behaviours are called impulse control disorders and can include addictive gambling, excessive eating or spending, an abnormally high sex drive or a preoccupation with an increase in sexual thoughts or feelings. 
Takva ponašanja se nazivaju poremećaji kontrole impulsa te mogu uključivati ovisničko kockanje, prekomjerno jedenje ili trošenje, nenormalno jak seksualni nagon ili preokupaciju s povećanjem seksualnih misli ili osjećaja.
For any information about this medicinal product, please contact the local representative of the Marketing Authorisation Holder. 
Za sve informacije o ovom lijeku obratite se lokalnom predstavniku nositelja odobrenja za stavljanje gotovoga lijeka u promet:
The NMS consists of some or all of the following: severe muscle stiffness, jerking movements of muscles, arms or legs, and soreness of muscles. 
NMS se sastoji od nekih ili svih od sljedećih simptoma: - jaka mišićna ukočenost, trzajni pokreti mišića, ruku ili nogu i bol mišića.
You should not breast-feed your infant during treatment with Tasmar. 
Ne smijete dojiti dijete tijekom liječenja Tasmarom.
*: Adverse reactions for which no frequency could be derived from clinical studies (i.e. where a specific adverse reaction was not observed in clinical trials but was reported post-marketing only) are indicated by an asterisk (*), and the frequency category has been calculated according to EU Guideline. 
: Nuspojave čija se učestalost nije mogla odrediti u kliničkim ispitivanjima (tj. kada specifične nuspojave nisu primjećene tijekom kliničkih ispitivanja već je izviješteno o njima samo nakon stavljanja lijeka u promet) označene su zvjezdicom (*), a kategorija učestalosti izračunana je prema EU smjernicama.
Inform your doctor also: - if you have any illnesses other than Parkinson's disease, - if you are allergic to other medicines, food and dyes, - if soon after beginning and during treatment with Tasmar you have symptoms which may be caused by levodopa such as involuntary movement (dyskinesia) and nausea. 
Također obavijestite svog liječnika: - ako imate bilo koju drugu bolest pored Parkinsonove bolesti, - ako ste alergični na druge lijekove, hranu i boje, - ako ubrzo nakon početka te tijekom liječenja Tasmarom imate simptome koje je mogla prouzročiti levodopa, kao što su nevoljni pokreti (diskinezija) i mučnina.
However, a study in Parkinson's patients confirmed that after treatment discontinuation there was no significant change in levodopa pharmacokinetics or in patient response to levodopa compared to pretreatment levels. 
Međutim, ispitivanje bolesnika s Parkinsonovom bolešću potvrdilo je da nakon prestanka liječenja nije bilo značajne promjene u farmakokinetici levodope ili u bolesnikovu odgovoru na levodopu, u odnosu na razine prije liječenja.
Liver injury: 
Oštećenje jetre:
No dose adjustment of Tasmar is recommended for patients with mild or moderate renal impairment (creatinine clearance of 30 ml/min or greater). 
Nije preporučena prilagodba doze Tasmara za bolesnike s blagim ili umjerenim oštećenjem bubrega (klirens kreatinina od 30 ml/min ili veći).
The average reduction in daily levodopa dose was about 30 % in those patients requiring a levodopa dose reduction. 
Prosječno smanjenje dnevne doze levodope bilo je oko 30 % u onih bolesnika kojima je bilo potrebno smanjiti dozu lovodope.
In all cases, patients should be educated on the symptoms of levodopa under-dose and what to do if it occurs. 
U svakom slučaju, bolesnici bi trebali biti educirani o simptomima premale doze levodope i što činiti ako do toga dođe.
Tasmar used with your other Parkinson medicines can cause excessive drowsiness (somnolence ) and sudden sleep onset episodes (you may suddenly fall asleep). 
Tasmar primijenjen s drugim lijekovima za Parkinsonovu bolest može prouzročiti prekomjernu omamljenost (somnolenciju) i epizode iznenadnog nastupa sna (možete iznenada zaspati).
Tolcapone is an orally active, selective and reversible catechol-O-methyltransferase (COMT) inhibitor. 
Tolkapon je oralno aktivni, selektivni i reverzibilni inhibitor katehol-O-metiltransferaze (COMT).
However patients should be advised that their ability to drive and operate machines may be compromised due to their Parkinson's disease symptoms. 
Međutim, bolesnike treba upozoriti da njihova sposobnost upravljanja vozilima i rada sa strojevima može biti ugrožena zbog simptoma Parkinsonove bolesti.
No effects were seen on the pharmacokinetics of the COMT substrate carbidopa. 
Nisu opaženi učinci na farmakokinetiku COMTovog supstrata karbidope.
In about half the cases, transaminase levels returned spontaneously to baseline values whilst patients continued Tasmar treatment. 
U otprilike polovini slučajeva razine transaminaza su se spontano vratile na početne vrijednosti tijekom nastavka bolesnikova liječenja Tasmarom.
Possible side effects Like all medicines, this medicine can have side effects, although not everybody gets them. 
Kao i svi lijekovi, ovaj lijek može uzrokovati nuspojave iako se one neće javiti kod svakoga.
However, in patients with moderate cirrhotic liver disease, clearance of unbound tolcapone was reduced by almost 50 %. 
Međutim, u bolesnika s umjerenom cirotičnom bolešću jetre, klirens nevezanog tolkapona bio je smanjen za gotovo 50 %.
ICN Polfa Rzeszów S.A. ul. 
ICN Polfa Rzeszów S.A. ul. Przemysłowa 2
Nausea, vomiting and dizziness were observed, particularly in combination with levodopa. 
Opažene su mučnina, povraćanje i omaglica, osobito u kombinaciji s levodopom.
Phaeochromocytoma. 
• Feokromocitom.
UNIQUE IDENTIFIER - HUMAN READABLE DATA 
18. JEDINSTVENI IDENIFIKATOR- PODACI ČITLJIVI LJUDSKIM OKOM
Tasmar should be discontinued if substantial clinical benefits are not seen within 3 weeks of the initiation of the treatment regardless of dose. 
Liječenje Tasmarom treba prekinuti ako se značajne kliničke koristi ne opaze unutar 3 tjedna od početka liječenja, neovisno o dozi.
Rarely, after abruptly reducing or stopping Tasmar or other antiparkinsonian drugs, you may experience severe symptoms of muscle stiffening, fever or mental confusion. 
Rijetko, nakon naglog smanjenja ili prestanka liječenja Tasmarom ili drugim antiparkinsonicima, možete iskusiti teške simptome mišićne ukočenosti, vrućicu ili mentalnu smetenost.
In an interaction study, tolcapone did not change the pharmacokinetics of tolbutamide. 
U ispitivanju interakcija tolkapon nije promijenio farmakokinetiku tolbutamida.
Do not use after the expiry date stated on the pack. 
Ne smije se upotrijebiti nakon isteka roka valjanosti navedenog na pakiranju.
Urine discolouration: Tolcapone and its metabolites are yellow and can cause a harmless intensification in the colour of the patient's urine. 
Diskoloracija urina: tolkapon i njegovi metaboliti su žuti i mogu prouzročiti neškodljivu intenzivniju boju urina kod bolesnika.
When Tasmar is administered together with levodopa, it increases the relative bioavailability (AUC) of levodopa approximately twofold. 
Kada se Tasmar primjenjuje zajedno s levodopom, relativna bioraspoloživost (AUC) levodope povećava se približno dva puta.
The first tablet Tasmar is to be taken in the morning together with your other parkinsonian medicine ‘levodopa'. 
Prvu tabletu Tasmara trebate uzeti ujutro zajedno s Vašim drugim lijekom za Parkinsonovu bolest ‘levodopom'.
The combination of MAO-A and MAO-B inhibitors is equivalent to non-selective MAO-inhibition, therefore they should not both be given concomitantly with Tasmar and levodopa preparations (see also section 4.5). 
Kombinacija MAO-A i MAO-B inhibitora istovjetna je neselektivnoj MAO-inhibiciji, stoga se oba ne bi smjela davati istodobno s Tasmarom i pripravcima levodope (vidjeti također dio 4.5).
Symptoms of overdose may include nausea, vomiting, dizziness and breathing difficulties. 
Simptomi predoziranja mogu uključivati mučninu, povraćanje, omaglicu i otežano disanje.
Carcinogenesis, mutagenesis: 3 % and 5 % of rats in the mid- and high- dose groups, respectively, of the 24-month carcinogenicity study were shown to have renal epithelial tumours (adenomas or carcinomas). 
Karcinogeneza, mutageneza: u ispitivanju kancerogenosti od 24 mjeseca pokazalo se da 3 % i 5 % štakora u skupinama srednjih, odnosno, visokih doza ima bubrežne epitelijalne tumore (adenome ili karcinome).
Number (proportion) with ≥1 hour ON time response 32 (43 %) 40 (53 %) p=0.191 -5.2;26.6 Secondary Outcome 
Broj (udio) s odgovorom od ≥ 1 sat u ON vremenu 32 (43 %) 40 (53 %) p=0,191 -5,2;26,6 Sekundarni ishod
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS 
PODACI KOJE NAJMANJE MORA SADRŽAVATI BLISTER ILI STRIP PAKIRANJE
Soon after beginning and during your treatment with Tasmar, you may have symptoms caused by levodopa such as involuntary movement and nausea. 
Ubrzo nakon početka te tijekom liječenja Tasmarom možda ćete imati simptome prouzročene levodopom kao što su nevoljni pokreti i mučnina.
Uncommon: liver injury, in rare cases with fatal outcome 
Manje često: oštećenje jetre, u rijetkim slučajevima sa smrtnim ishodom
No studies on the effects of Tasmar on the ability to drive and use machines have been performed. 
Nisu provedena ispitivanja učinaka Tasmara na sposobnost upravljanja vozilima i rada sa strojevima.
If you have been already treated with Tasmar and developed acute liver injury during treatment, Tasmar should not be re-introduced again. 
Ako ste se već liječili Tasmarom i razvili akutno oštećenje jetre tijekom liječenja, ne biste se smjeli ponovno liječiti Tasmarom.
Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a firstline adjunct therapy to levodopa/benserazide or levodopa/carbidopa (see sections 4.4 and 4.8). 
Zbog rizika od potencijalno smrtonosnog, akutnog oštećenja jetre, Tasmar se ne smije razmatrati kao prva linija adjuvantne terapije levodopi/benzerazidu ili levodopi/karbidopi (vidjeti dijelove 4.4 i 4.8).
Studies in healthy volunteers have shown that tolcapone reversibly inhibits human erythrocyte COMT activity after oral administration. 
Ispitivanja na zdravim dobrovoljcima pokazala su da tolkapon reverzibilno inhibira aktivnost COMT-a ljudskih eritrocita nakon peroralne primjene.
General supportive care is indicated. 
Indicirana je opća suportivna njega.
During the day 1 film-coated tablet Tasmar Evening 
Tijekom dana 1 filmom obložena tableta Tasmar Večer
The effects of Tasmar have not been studied in infants. 
Učinci Tasmara nisu ispitivani u dojenčadi.
Selective MAO-B inhibitors should not be used at higher than recommended doses (e.g. selegiline 10 mg/day) when coadministered with Tasmar. 
Selektivni MAO-B inhibitori ne smiju se uzimati u dozama većim od preporučenih (npr. selegilin 10 mg/dan) kada se primjenjuju istodobno s Tasmarom.
Tasmar contains lactose 
Tasmar sadrži laktozu
Adjustments in levodopa are most likely to be required within 1-2 days of Tasmar discontinuation. 
Prilagodbe levodope će najvjerojatnije biti potrebne untar 1-2 dana nakon prekida liječenja Tasmarom.
The effect of tolcapone on the pharmacokinetics of other drugs metabolised by COMT such as -methyldopa, dobutamine, apomorphine, adrenaline and isoprenaline have not been evaluated. 
Učinak tolkapona na farmakokinetiku drugih lijekova metaboliziranih COMTom, kao što su -metildopa, dobutamin, apomorfin, adrenalin i izoprenalin još nije procijenjen.
Benserazide interaction: Due to the interaction between high dose benserazide and tolcapone (resulting in increased levels of benserazide), the prescriber should, until more experience has been gained, be observant of dose-related adverse reactions (see section 4.5). 
Interakcija s benzerazidom: zbog interakcije između visokih doza benzerazida i tolkapona (što rezultira povišenim razinama benzerazida), liječnik koji propisuje lijek treba paziti na nuspojave ovisne o dozi dok se ne stekne više iskustva (vidjeti dio 4.5).
Liver injury has most often occurred between 1 month and 6 months after starting treatment with Tasmar. 
Oštećenje jetre se najčešće javljalo između 1 mjeseca i 6 mjeseci nakon početka liječenja Tasmarom.
Levodopa dose should not be decreased when Tasmar therapy is being discontinued due to side effects related to too much levodopa. 
Dozu levodope se ne bi smjelo smanjiti pri prekidu terapije Tasmarom zbog nuspojava povezanih s previše levodope.
Before starting treatment: To reduce the risk of NMS, Tasmar should not be prescribed for patients with severe dyskinesia or a previous history of NMS including rhabdomyolysis or hyperthermia (see section 4.3). 
Prije početka liječenja: radi smanjenja rizika od NMS-a, Tasmar ne treba propisivati bolesnicima s teškom diskinezijom ili s prethodnom anamnezom NMS-a, uključujući rabdomiolizu ili hipertermiju (vidjeti dio 4.3).
If you stop taking Tasmar 
Ako prestanete uzimati Tasmar
Catechols and other drugs metabolised by catechol-O-methyltransferase (COMT): Tolcapone may influence the pharmacokinetics of drugs metabolised by COMT. 
Kateholi i drugi lijekovi metabolizirani katehol-O-metiltransferazom (COMT): tolkapon može utjecati na farmakokinetiku lijekova metaboliziranih COMT-om.
Double blind placebo controlled clinical studies have shown a significant reduction of approximately 20 % to 30 % in OFF time and a similar increase in ON time, accompanied by reduced severity of symptoms in fluctuating patients receiving Tasmar. 
Dvostruko slijepa placebom kontrolirana klinička ispitivanja pokazala su značajno smanjenje od otprilike 20 % do 30 % u OFF vremenu te slično povećanje u ON vremenu, popraćeno sa smanjenom težinom simptoma u fluktuirajućim bolesnicima koji su primali Tasmar.
Therefore, if you feel unwell, you should contact your doctor since you may need to have your levodopa dose changed. 
Stoga, ako se osjećate loše, trebate se obratiti svom liječniku jer će možda biti potrebno promijeniti Vašu dozu levodope.
Tasmar treatment should also be discontinued if ALT (alanine amino transferase) and/or AST (aspartate amino transferase) exceed the upper limit of normal or symptoms or signs suggest the onset of hepatic failure (see section 4.4). 
Liječenje Tasmarom treba prekinuti i ako ALT (alanin aminotransferaza) i/ili AST (aspartat aminotransferaza) premašuju gornju granicu normale ili ako simptomi ili znakovi upućuju na nastup zatajenja jetre (vidjeti dio 4.4).
If substantial clinical benefits are not seen within 3 weeks of the initiation of the treatment (regardless of dose) Tasmar should be discontinued. 
Ako se značajna klinička korist ne opazi unutar 3 tjedna od početka liječenja (bez obzira na dozu), Tasmar treba ukinuti.
Do not break or crush tablet. 
Nemojte lomiti ili drobiti tabletu.
Experience with Tasmar obtained in parallel placebo-controlled randomised studies in patients with Parkinson's disease is shown in the following table, which lists adverse reactions with a potential relationship to Tasmar. 
Iskustvo s Tasmarom dobiveno u paralelnim randomiziranim placebom kontroliranim ispitivanjima u bolesnika s Parkinsonovom bolešću prikazano je u sljedećoj tablici koja navodi nuspojave potencijalno povezane s Tasmarom.
1 film-coated tablet Tasmar Together with the first daily dose ´levodopa' 
1 filmom obložena tableta Tasmar Zajedno s prvom dnevnom dozom ´levodope'
If you have forgotten several doses, please inform your doctor and follow the advice given to you. 
Ako ste zaboravili nekoliko doza, obavijestite svog liječnika te primijenite savjet koji ste dobili.